GO:0000389 mRNA 3'-splice site recognition: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000389 (mRNA 3'-splice site recognition) is the biological process in which the assembling spliceosome identifies the intron 3' splice site, a critical step for accurate exon ligation.
• The U2AF heterodimer (U2AF1/U2AF2) and associated factors such as FUBP1 facilitate 3' splice site recognition, particularly for long introns and weak polypyrimidine tracts.
• Mutations in 3' splice site recognition components or in the splice site itself cause human diseases, including myelodysplastic syndromes and inherited disorders such as neurofibromatosis type 1 and cardiomyopathies.
• Cryptic 3' splice site activation, as seen in STMN2 upon TDP-43 loss, highlights the importance of this process in neurodegeneration.
• Experimental models using CRISPR knockout, point mutations, and knock-in reporters are essential to dissect the molecular mechanisms and disease relevance of 3' splice site recognition.
• Understanding mRNA 3'-splice site recognition informs therapeutic strategies targeting splicing in cancer and genetic disorders.
Description
Accurate pre-mRNA splicing is essential for gene expression in eukaryotes, and the recognition of the 3' splice site is a key step in this process. GO:0000389, mRNA 3'-splice site recognition, is defined as the recognition of the intron 3'-splice site by components of the assembling U2- or U12-type spliceosome. This process ensures that the spliceosome correctly identifies the boundary between the intron and the downstream exon, which is critical for the fidelity of exon ligation and the production of functional mRNAs. Defects in this recognition step can lead to aberrant splicing, including exon skipping or intron retention, which are associated with numerous human diseases. The spliceosome is a dynamic ribonucleoprotein machine that undergoes extensive rearrangements during splice site recognition and catalysis. The 3' splice site is typically defined by a polypyrimidine tract and a conserved AG dinucleotide, and its recognition involves multiple protein factors, including U2AF1, U2AF2, and other auxiliary proteins. Recent studies have revealed that the recognition process is highly regulated and can be influenced by intron length, sequence context, and the presence of splicing enhancers or silencers. For example, FUBP1 has been identified as a general splicing factor that facilitates 3' splice site recognition, especially for long introns. Given the central role of 3' splice site recognition in gene expression, mutations in the components of this machinery or in the splice site sequences themselves can have profound consequences. Indeed, mutations in U2AF1 and other splicing factors are frequent in myelodysplastic syndromes and other cancers. Moreover, cryptic 3' splice site activation due to loss of TDP-43 function contributes to neurodegeneration, as seen in amyotrophic lateral sclerosis (ALS). Therefore, studying mRNA 3'-splice site recognition is not only fundamental to understanding RNA processing but also has direct implications for human health and disease.
mRNA 3'-splice site recognition At A Glance
| GO ID | GO:0000389 |
|---|---|
| GO term | mRNA 3'-splice site recognition |
| Ontology | biological_process |
| Synonym | nuclear mRNA 3'-splice site recognition; U12-type nuclear mRNA 3'-splice site recognition; U2-type nuclear mRNA 3'-splice site recognition |
| Major function | Recognition of the intron 3'-splice site by components of the assembling U2- or U12-type spliceosome |
| Related cellular component | Spliceosome (U2/U12 snRNPs and associated proteins) |
| Related molecular function | RNA binding, sequence-specific DNA/RNA recognition |
| Key factors | U2AF1, U2AF2, FUBP1, SF1, U2 snRNP, and other spliceosomal proteins |
What Is GO:0000389?
mRNA 3'-splice site recognition (GO:0000389) is the biological process in which the spliceosome, during its assembly on a pre-mRNA transcript, identifies the 3' splice site of an intron. This recognition involves the binding of specific spliceosomal components to the polypyrimidine tract and the AG dinucleotide at the intron-exon boundary, thereby defining the site for the second catalytic step of splicing. The process is essential for the accurate removal of introns and joining of exons in both U2- and U12-type introns.
Why Is mRNA 3'-splice site recognition Important in Cell Biology?
mRNA 3'-splice site recognition is a critical determinant of splicing fidelity and proteome diversity. Errors in this process can lead to aberrant splicing, which is a common cause of genetic disorders and cancer. Moreover, the recognition step is a point of regulation where splicing can be modulated in response to cellular signals, making it a potential therapeutic target.
• Ensures accurate intron removal and exon joining, which is essential for mRNA maturation and protein function.
• Mutations in 3' splice site sequences or in the recognition machinery cause inherited diseases such as neurofibromatosis type 1 and cardiomyopathies.
• Dysregulation of 3' splice site recognition is implicated in myelodysplastic syndromes and leukemias through mutations in splicing factors like U2AF1.
• Cryptic 3' splice site activation contributes to neurodegeneration, as exemplified by STMN2 mis-splicing in TDP-43 proteinopathies.
• The process is a target for antisense oligonucleotide and small molecule therapies aimed at correcting splicing defects.
• Understanding 3' splice site recognition aids in interpreting the functional consequences of non-coding genetic variants.
• It is essential for the splicing of long introns, which are prevalent in human genes, and factors like FUBP1 facilitate this.
• Dynamic cycling of U2AF defines phases of cotranscriptional splicing, linking transcription and splicing.
• Research on this process provides insights into the evolution of spliceosomal introns and alternative splicing.
• Experimental models of 3' splice site recognition are crucial for drug discovery and functional genomics.
What Happens During mRNA 3'-splice site recognition?
Initial recognition of the polypyrimidine tract and AG dinucleotide
In simple terms: The spliceosome first looks for a short sequence rich in pyrimidines and a specific AG pair at the end of the intron.
During the early stages of spliceosome assembly, the 3' splice site is recognized by factors such as U2AF (U2 auxiliary factor), which binds to the polypyrimidine tract and the AG dinucleotide at the intron-exon boundary. This initial recognition is crucial for defining the 3' splice site and is facilitated by proteins like FUBP1, which aids in the recognition of weak or distant 3' splice sites, particularly in long introns. The binding of U2AF is a dynamic process that couples with transcription.
Role of U2AF and associated factors
In simple terms: A protein called U2AF grabs the 3' end of the intron and helps position the spliceosome for cutting.
U2AF is a heterodimer composed of a large subunit (U2AF2) that binds the polypyrimidine tract and a small subunit (U2AF1) that interacts with the AG dinucleotide. This interaction is essential for the recruitment of the U2 snRNP to the branch point sequence, which is a prerequisite for the first catalytic step of splicing. Mutations in U2AF1 are associated with myelodysplastic syndromes, highlighting its importance in disease.
ATP-dependent rearrangements and proofreading
In simple terms: The spliceosome uses energy to check that it has found the right 3' splice site before cutting.
After initial recognition, ATP-dependent RNA helicases remodel the spliceosome to ensure fidelity. This proofreading step discriminates between authentic and cryptic 3' splice sites. The dynamic cycling of U2AF and other factors defines two phases of cotranscriptional splicing, allowing for quality control.
Coupling with transcription and other processing events
In simple terms: The recognition of the 3' splice site happens while the RNA is still being made, and it is coordinated with other steps.
3' splice site recognition is coupled with transcription and other RNA processing events, such as 5' capping and 3' end formation. This coupling ensures that splicing occurs efficiently and accurately. Factors like FUBP1 may also coordinate with the transcription machinery to facilitate splicing of long introns.
Key Genes Involved in GO:0000389 mRNA 3'-splice site recognition
The following genes encode proteins that are directly involved in or regulate mRNA 3'-splice site recognition, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| U2AF1 | Small subunit of U2AF, binds AG dinucleotide and interacts with U2AF2 | Mutations in U2AF1 are frequent in myelodysplastic syndromes and alter 3' splice site recognition |
| U2AF2 | Large subunit of U2AF, binds polypyrimidine tract | Essential for 3' splice site recognition; target for splicing modulation |
| FUBP1 | Facilitates 3' splice site recognition and splicing of long introns | Knockdown affects splicing of long introns; potential role in cancer |
| SF1 | Binds branch point sequence and aids in 3' splice site recognition | Component of early spliceosomal complex E |
| U2 snRNP | Recognizes branch point and interacts with 3' splice site factors | Central to spliceosome assembly |
| TDP-43 | RNA-binding protein that represses cryptic 3' splice site usage | Loss leads to STMN2 cryptic splicing in ALS |
| STMN2 | Neuron-specific protein; its cryptic 3' splice site is activated upon TDP-43 loss | Biomarker and therapeutic target in TDP-43 proteinopathies |
| NF1 | Tumor suppressor; intronic mutations create or alter 3' splice sites | Mutations outside canonical AG affect splicing and cause neurofibromatosis type 1 |
| LMNA | Nuclear lamina protein; mutations can create cryptic 3' splice sites | Splicing mutations cause laminopathies |
| MYBPC3 | Cardiac myosin-binding protein; mutations affect splicing | Splicing mutations cause hypertrophic cardiomyopathy |
| PRPF8 | Core spliceosomal protein | Mutations in PRPF8 affect 3' splice site recognition and cause retinitis pigmentosa |
| SF3B1 | Component of U2 snRNP | Mutations in SF3B1 are common in myelodysplastic syndromes and alter 3' splice site selection |
| SRSF1 | SR protein that modulates splice site selection | Regulates 3' splice site recognition through enhancer binding |
| HNRNPA1 | hnRNP protein that can antagonize 3' splice site recognition | Modulates splicing and is implicated in neurodegeneration |
| RBM39 | Splicing factor associated with U2AF | Regulates 3' splice site recognition and is a target in cancer |
| DDX5 | RNA helicase involved in spliceosome dynamics | Facilitates 3' splice site recognition and splicing |
| DDX17 | RNA helicase involved in spliceosome dynamics | Facilitates 3' splice site recognition and splicing |
| PTBP1 | Polypyrimidine tract binding protein | Represses 3' splice site recognition in a context-dependent manner |
How Is mRNA 3'-splice site recognition Regulated?
The process of mRNA 3'-splice site recognition is regulated at multiple levels. Transcription elongation rates can influence the time available for splice site recognition, and dynamic cycling of U2AF defines two phases of cotranscriptional splicing. Additionally, the expression and activity of splicing factors such as FUBP1 and SR proteins are modulated by cellular signaling pathways, including those involved in growth and stress responses. For example, FUBP1 levels can affect the efficiency of 3' splice site recognition for long introns. Furthermore, mutations in splicing factors like U2AF1 can alter the preference for specific 3' splice sites, leading to aberrant splicing patterns in disease.
mRNA 3'-splice site recognition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| U2AF1 | Myelodysplastic syndromes, leukemia | Knock-in of mutant U2AF1 in hematopoietic stem cells; KO in cell lines |
| STMN2 | ALS, TDP-43 proteinopathies | CRISPR knock-in of cryptic 3' splice site reporter; TDP-43 KO neurons |
| NF1 | Neurofibromatosis type 1 | Minigene splicing reporter with patient mutations; KO of NF1 in cell lines |
| LMNA | Laminopathies, cardiomyopathy | Point mutation knock-in in iPSCs; minigene assays |
| MYBPC3 | Hypertrophic cardiomyopathy | Knock-in of splicing mutation in cardiomyocytes; KO models |
Myelodysplastic syndromes and cancer
Mutations in splicing factors such as U2AF1 and SF3B1 are frequent in myelodysplastic syndromes and other cancers, and they often affect 3' splice site recognition, leading to altered splicing of genes involved in hematopoiesis and tumor suppression. These mutations can change the preference for the AG dinucleotide or the polypyrimidine tract, resulting in aberrant exon inclusion or skipping.
Neurodegeneration
In TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, loss of nuclear TDP-43 leads to the activation of cryptic 3' splice sites in genes such as STMN2. This mis-splicing results in reduced STMN2 protein levels, contributing to neuronal dysfunction. Correction of this cryptic splicing is a potential therapeutic strategy.
Inherited genetic disorders
Mutations that create or disrupt 3' splice sites cause a variety of inherited diseases. For example, intronic mutations in NF1 that affect 3' splice site recognition can lead to neurofibromatosis type 1. Similarly, mutations in LMNA and MYBPC3 that alter splicing are associated with laminopathies and cardiomyopathies, respectively. These mutations often affect the canonical AG dinucleotide or nearby sequences, highlighting the importance of accurate 3' splice site recognition.
From mRNA 3'-splice site recognition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of U2AF1 mutation on 3' splice site recognition? | Knock-in of mutant U2AF1 in cell lines (e.g., K562) followed by RNA-seq |
| How does TDP-43 loss affect cryptic 3' splice site usage? | TDP-43 knockout in neuronal cell lines or iPSC-derived neurons with STMN2 reporter |
| Does a specific intronic variant alter 3' splice site recognition? | Minigene splicing reporter with wild-type and mutant sequences in HEK293T cells |
| What proteins interact with U2AF at the 3' splice site? | Knock-in of tagged U2AF1 (e.g., GFP) for immunoprecipitation and mass spectrometry |
| Can overexpression of FUBP1 rescue splicing of long introns? | Overexpression of FUBP1 in cells with long intron reporters |
| What is the global impact of splicing factor knockdown on 3' splice site usage? | CRISPR knockout of splicing factors followed by RNA-seq and bioinformatics |
How to Study the mRNA 3'-splice site recognition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global changes in splicing, including 3' splice site usage | Comparing mutant and wild-type cells to identify mis-splicing events |
| Minigene assay | Splicing efficiency of a specific 3' splice site | Validating the impact of patient mutations on splicing |
| CRISPR screen | Identification of genes regulating 3' splice site recognition | Functional genomics to discover novel splicing factors |
| CLIP-seq | RNA binding sites of splicing factors | Mapping U2AF1 or FUBP1 binding near 3' splice sites |
| Mass spectrometry | Protein-protein interactions in spliceosomal complexes | Identifying components of the 3' splice site recognition machinery |
| RT-PCR | Specific splicing isoforms | Confirming splicing changes observed by RNA-seq |
| In vitro splicing | Biochemical steps of 3' splice site recognition | Mechanistic studies using nuclear extracts |
| Reporter cell lines | Real-time monitoring of 3' splice site usage | High-throughput drug screening |
RNA-seq and splicing analysis
RNA sequencing (RNA-seq) is a powerful method to assess global changes in 3' splice site recognition. By comparing wild-type and mutant cells, researchers can identify differential exon inclusion, intron retention, and alternative 3' splice site usage. Computational tools such as rMATS or MAJIQ can quantify splicing events and predict the impact of mutations.
Minigene splicing reporters
Minigene reporters are designed to contain a specific exon and flanking introns with the 3' splice site of interest. Transfection into cells allows direct measurement of splicing efficiency and the effect of mutations. This method is particularly useful for validating the pathogenicity of variants found in patients.
CRISPR-based screens
CRISPR knockout or interference screens can identify genes that regulate 3' splice site recognition. By using reporters that express a fluorescent protein only when a specific 3' splice site is used, researchers can sort cells and identify regulators. Such screens have uncovered novel splicing factors and therapeutic targets.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) can identify proteins that interact with the 3' splice site recognition machinery. Tagged U2AF1 or other factors can be used to pull down complexes from nuclear extracts, revealing dynamic interactions.
How CRISPR Can Be Used to Study GO:0000389 mRNA 3'-splice site recognition
Knockout
CRISPR knockout of genes involved in 3' splice site recognition, such as U2AF1 or FUBP1, can reveal their essential roles in splicing and cell viability. For example, knockout of FUBP1 in cell lines leads to increased intron retention in long introns, demonstrating its importance in 3' splice site recognition. Knockout models are also used to study the consequences of loss of function in disease contexts.
Point Mutation
CRISPR-mediated point mutations can mimic disease-associated mutations in splicing factors or splice sites. For instance, introducing the U2AF1 S34F mutation into cells recapitulates the aberrant splicing patterns seen in myelodysplastic syndromes. Similarly, point mutations in the 3' splice site of NF1 can be introduced to study their impact on splicing.
Knock-in
Knock-in of reporter cassettes or tagged proteins allows precise tracking of 3' splice site recognition. For example, knocking in a fluorescent reporter that is activated upon correct 3' splice site usage enables live-cell imaging and screening. Tagged knock-in of U2AF1 with GFP facilitates localization and interaction studies.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can be used to overexpress splicing factors like FUBP1 to test their ability to enhance 3' splice site recognition. Overexpression of FUBP1 rescues splicing defects in cells with long introns, highlighting its role. Overexpression models are also useful for studying gain-of-function mutations.
How EDITGENE Supports mRNA 3'-splice site recognition Research
Researchers studying mRNA 3'-splice site recognition-related genes often need to determine whether a candidate gene is causally involved in splicing regulation or disease. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides comprehensive services to generate such models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for mRNA 3'-splice site recognition research.
Frequently Asked Questions About mRNA 3'-splice site recognition
What is mRNA 3'-splice site recognition?
mRNA 3'-splice site recognition (GO:0000389) is the process by which the spliceosome identifies the 3' end of an intron, involving the recognition of the polypyrimidine tract and AG dinucleotide by factors such as U2AF.
What genes are involved in mRNA 3'-splice site recognition?
Key genes include U2AF1, U2AF2, FUBP1, SF1, and components of the U2 snRNP, as well as regulatory factors like TDP-43 and SR proteins.
How does U2AF recognize the 3' splice site?
U2AF is a heterodimer: U2AF2 binds the polypyrimidine tract, while U2AF1 interacts with the AG dinucleotide at the intron-exon boundary, positioning the spliceosome for catalysis.
What diseases are associated with defects in 3' splice site recognition?
Mutations in splicing factors like U2AF1 cause myelodysplastic syndromes; cryptic 3' splice site activation contributes to ALS; and intronic mutations in NF1, LMNA, and MYBPC3 cause inherited disorders.
How can I study mRNA 3'-splice site recognition in the lab?
Common methods include RNA-seq, minigene reporters, CRISPR screens, and proteomics. These approaches allow assessment of splicing efficiency and identification of regulatory factors.
What is the role of FUBP1 in 3' splice site recognition?
FUBP1 is a general splicing factor that facilitates 3' splice site recognition, particularly for long introns, by aiding in the recruitment of U2AF and other components.
How does TDP-43 affect 3' splice site recognition?
TDP-43 represses cryptic 3' splice sites; its loss leads to activation of cryptic sites in genes like STMN2, contributing to neurodegeneration.
Can CRISPR be used to model 3' splice site recognition defects?
Yes, CRISPR knockout, point mutation, and knock-in models can replicate disease-associated mutations and enable functional studies of splicing.
What is the difference between U2-type and U12-type 3' splice site recognition?
U2-type introns are recognized by the major spliceosome, while U12-type introns are recognized by the minor spliceosome; both involve distinct but analogous mechanisms.
Why is 3' splice site recognition important for cancer?
Mutations in splicing factors like U2AF1 and SF3B1 alter 3' splice site recognition, leading to aberrant splicing of oncogenes and tumor suppressors, which drives cancer development.
Conclusion
mRNA 3'-splice site recognition (GO:0000389) is a fundamental step in pre-mRNA splicing that ensures the fidelity of intron removal and exon joining. Dysregulation of this process, through mutations in splice site sequences or splicing factors, leads to a range of human diseases, including cancer, neurodegeneration, and inherited disorders. Continued research using advanced CRISPR models and high-throughput methods will further elucidate the mechanisms and therapeutic potential of targeting 3' splice site recognition.
References
- 1. Baughn MW et al.. 2023. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.. Science 379(6637):1140-1149 PMID: 36927019
- 2. Ebersberger S et al.. 2023. FUBP1 is a general splicing factor facilitating 3' splice site recognition and splicing of long introns.. Mol Cell 83(15):2653-2672.e15 PMID: 37506698
- 3. Wimmer K et al.. 2020. AG-exclusion zone revisited: Lessons to learn from 91 intronic NF1 3' splice site mutations outside the canonical AG-dinucleotides.. Hum Mutat 41(6):1145-1156 PMID: 32126153
- 4. Ito K et al.. 2017. Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing.. Proc Natl Acad Sci U S A 114(29):7689-7694 PMID: 28679633
- 5. Shao C et al.. 2025. Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing.. Science 389(6767):eadj9141 PMID: 40997183
- 6. Anna A et al.. 2018. Splicing mutations in human genetic disorders: examples, detection, and confirmation.. J Appl Genet 59(3):253-268 PMID: 29680930
- 7. Wahl MC et al.. 2009. The spliceosome: design principles of a dynamic RNP machine.. Cell 136(4):701-18 PMID: 19239890
- 8. Yoshida K et al.. 2011. Frequent pathway mutations of splicing machinery in myelodysplasia.. Nature 478(7367):64-9 PMID: 21909114
